Compare

GSK plc/£GSK

1D1W1M3M6MYTD1Y5YMAX

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
£GSK
Sector
Health
Primary listing
LSE
Employees
66,841

GSK plc Metrics

BasicAdvanced
£73B
17.12
£1.07
0.28
£0.68
3.72%

What the Analysts think about GSK plc

Analyst ratings (Buy, Hold, Sell) for GSK plc stock.
Analyst projections of the future price of GSK plc stock.

Bulls say / Bears say

Specialty medicines are driving growth: Q3 sales rose 15%, led by HIV up 10%, respiratory, immunology and inflammation up 21%, and oncology up 23%. GSK reaffirmed its 2026 guidance. (GSK)
The pipeline offers further growth catalysts: GSK reported positive registrational data for lung-cancer drug Ris-Rez and approvals for Hibsago and Jemperli, and is on track to start 22 Phase III trials in 2026. (GSK)
Jideytro’s US approval gives GSK its first foothold in lung cancer, while the acquired Nuvalent portfolio includes another late-stage candidate, neladalkib, under FDA review. This creates an opportunity to build a new oncology business. (GSK)
Vaccine sales weakened in Q3: the segment fell 2%, with Shingrix down 5% and Arexvy down 24%. This could offset growth elsewhere if demand remains soft. (GSK)
Reported earnings were pressured: Q3 total operating profit fell 16% and total EPS fell 21%, while core EPS rose only 1%. Management expects full-year core EPS growth in the lower half of its 7%–9% range. (GSK, Reuters)
Clinical pipeline risk remains high: GSK stopped developing camlipixant after late-stage chronic-cough studies missed key goals, and separately ended its Alector partnership after setbacks to two neuroscience candidates. (Reuters, Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.

GSK plc Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

GSK plc Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.